fig3
![Clinical resistance predictors to first-line VEGFR-TKI monotherapy for metastatic renal cell carcinoma: a retrospective multicenter real-life case series](https://image.oaes.cc/ec15dec8-182f-4c3a-b255-8973f3abea92/jcmt3041.fig.3.jpg)
Figure 3. Progression-Free Survival probability to VEGFR-TKI monotherapy in first-line according to time after therapy initiation in the study population, divided by presence/absence of sarcomatoid features.
Figure 3. Progression-Free Survival probability to VEGFR-TKI monotherapy in first-line according to time after therapy initiation in the study population, divided by presence/absence of sarcomatoid features.
All published articles are preserved here permanently:
https://www.portico.org/publishers/oae/